<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521378</url>
  </required_header>
  <id_info>
    <org_study_id>DP 01-2007-01</org_study_id>
    <nct_id>NCT00521378</nct_id>
  </id_info>
  <brief_title>A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diasome Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diasome Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2007</start_date>
  <completion_date type="Actual">October 6, 2007</completion_date>
  <primary_completion_date type="Actual">October 6, 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dose response of postprandial plasma glucose to escalated doses of oral HDV-insulin</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine the dose response of postprandial plasma glucose to escalating doses (increased daily) of Oral HDV-Insulin given as single doses before breakfast, lunch and dinner, in addition to the Diabetes Mellitus (DM) subject's regular oral type 2 therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily glucodynamic profile of Oral HDV-Insulin</measure>
    <time_frame>3 weeks</time_frame>
    <description>To compare the daily glucodynamic profile of Oral HDV-Insulin over the treatment days</description>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Have a current diagnosis of type 2 DM, which is currently managed with oral hypoglycemic&#xD;
        agents for at least 3 months&#xD;
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must satisfy all of the following inclusion criteria to be included in the study:&#xD;
&#xD;
          1. be male or female between the ages of18 and 65 years, inclusive;&#xD;
&#xD;
          2. have a current diagnosis of type 2 DM, which is currently managed with oral&#xD;
             hypoglycemic agents for at least 3 months;&#xD;
&#xD;
          3. have a current physical examination that reveals no clinically significant&#xD;
             abnormalities;&#xD;
&#xD;
          4. have no clinically significant abnormalities in vital signs;&#xD;
&#xD;
          5. have a body mass index (BMI) &lt;38;&#xD;
&#xD;
          6. have a glycosylated hemoglobin (HbA1c) &gt; 8 and &lt;12;&#xD;
&#xD;
          7. have a C-peptide level &gt;3 ng/mL;&#xD;
&#xD;
          8. have a typical fasting blood glucose levels of &lt; 200 mg/dl (+/- 25 mg/dl);&#xD;
&#xD;
          9. be available for the entire study period, and be able and willing to adhere to&#xD;
             protocol requirements;&#xD;
&#xD;
         10. if female of childbearing potential, must be using a reliable form of birth control;&#xD;
             and,&#xD;
&#xD;
         11. provide written informed consent prior to admission into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have a history or presence of significant cardiac, gastrointestinal, endocrine,&#xD;
             neurological, liver, or kidney disease, or conditions known to interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of insulin;&#xD;
&#xD;
          2. have a history of drug or alcohol dependency or psychological disease;&#xD;
&#xD;
          3. have any clinically significant illness during the 4 weeks prior to admission into the&#xD;
             study;&#xD;
&#xD;
          4. require regular use of medication that interferes with the absorption and/or&#xD;
             metabolism of insulin;&#xD;
&#xD;
          5. recent use (within 48 hours) of medications that interfere with blood glucose&#xD;
             analyses, i.e., mannose, acetaminophen, dopamine, and ascorbic acid, which are all&#xD;
             reported to alter glucose-oxidase type blood glucose analytical methods;&#xD;
&#xD;
          6. use of Avandia or Actos for treating diabetes;&#xD;
&#xD;
          7. participation in a clinical trial or use of an investigational drug within 30 days&#xD;
             prior to admission to this study;&#xD;
&#xD;
          8. use of MAO inhibitors or enzyme-inducing or enzyme-inhibiting agents (eg,&#xD;
             phenobarbital or carbamazepine) within 30 days prior to admission to this study;&#xD;
&#xD;
          9. are pregnant or lactating; 10. have an episode of severe hypoglycemia with seizure or&#xD;
             coma within the past year;&#xD;
&#xD;
        11. have a history of ketoacidosis;&#xD;
&#xD;
        12. have any acute illness within 2 weeks prior to Screening; or,&#xD;
&#xD;
        13. have elevated liver enzymes (ALT, AST, alkaline phosphatase) &gt;1.5 times the upper limit&#xD;
        of normal.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 23, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 1 and Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

